Physician profile
Ledia Turner
NPI 1801279120
$993.55
in general payments reported to CMS, 2019-2025
19 companies · $644 in 2025
The $644 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $44.62 · 2024: $305 · 2025: $644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $949.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $948.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $93.40 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $91.69 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Exact Sciences Corporation | $86.60 | 2024-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $78.36 | 2025 | Mounjaro, Zepbound |
| Pfizer INC. | $67.57 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.43 | 2024-2025 | Jardiance, Synjardy |
| Abbott Laboratories | $66.98 | 2022-2024 | Freestyle Libre 3 |
| Novo Nordisk INC | $64.91 | 2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $61.71 | 2024-2025 | Shingrix, Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $58.24 | 2024-2025 | |
| Dexcom, INC. | $53.66 | 2024-2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $43.32 | 2024-2025 | Korlym |
| Amgen INC. | $31.23 | 2024-2025 | Krystexxa, Otezla, Repatha |
| Boston Scientific Corporation | $30.86 | 2025 | General - Pain Management |
| Bayer Healthcare Pharmaceuticals INC. | $28.89 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $18.60 | 2025 | Inspire |
| Philips North America LLC | $18.45 | 2025 | Vest Therapy Und |
| Actelion Pharmaceuticals US, INC. | $17.15 | 2025 | Uptravi, Opsumit |
| Xeris Pharmaceuticals, INC. | $14.50 | 2025 | Keveyis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ledia Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.